Trial
NCT04608266
CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
—
Condition
Covid19
Intervention
Camostat Mesylate
Why stopped
Scientific committee decision due SARS-CoV2 pandemic evolution with a decrease in inclusions and widespread distribution of vaccines
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-10